Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Next-Generation Antibody Therapies Market Forecast 2018-2028 - Visiongain Report

This image opens in the lightbox

News provided by

Visiongain

02 Oct, 2018, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, October 2, 2018 /PRNewswire/ --

Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies 

The global next-generation antibody therapies market reached $4bn in 2017 and is estimated to reach $17bn by 2023. In 2017, the antibody-drug conjugates segment held 45% of the global next-generation antibody therapies market.

     (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 217-page report you will receive 141 charts- all unavailable elsewhere.

The 217-page report provides clear detailed insight into the next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Next-Generation Antibody Therapies Market from 2018-2028

• Forecast of the Global Next-Generation Antibody Therapies market by Submarket:
• Antibody Fragments & ALPs
• Antibody-Drug Conjugates
• Biosimilar Antibodies
• Bispecific Antibodies
• Engineered Antibodies

• Forecast of the Global Antibody Fragments & ALPs submarket by Product:
• Kalbitor
• Other Antibody Fragments

• Forecast of the Global Antibody-Drug Conjugates submarket by Product:
• Adcetris
• Kadcyla
• Mylotarg
• Other ADCs

• Forecast of the Global Biosimilar Antibodies submarket by Product:
• Infliximab
• Adalimumab
• Rituximab
• Bevacizumab
• Trastuzumab
• Other Biosimilar mAbs

• Forecast of the Global Bispecific Antibodies submarket by Product:
• Blincyto
• Hemlibra
• Other Bispecific Antibodies

• Forecast of the Global Engineered Antibodies submarket by Product:
• Gazyva/Gazyvaro
• Poteligeo
• Fasenra
• Other Engineered Antibodies

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: US, Canada, and Mexico
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
• LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA

• Our study discusses the selected leading companies that are the major players in the next-generation antibody therapies market:
• Amgen, Inc.
• GlaxoSmithKline (GSK)
• Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.)
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Roche
• Sanofi
• Seattle Genetics, Inc.
• Shire plc

• This report discusses SWOT & STEP analysis of the next-generation antibody therapies market as well as factors that drive and restrain this market. This report also discusses the opportunities that can be tapped in this market.

• This report also discusses selected at that are in the pipeline.

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2018-2028: Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-next-generation-antibody-therapies-market-forecast-2018-2028/

AbbVie
AbGenomics
Ablynx
AdAlta
ADC Therapeutics
Adnexus
Affimed Therapeutics
Agensys
Alcon
Alexion
Algeta ASA
Allergan
ALMAC Group
Ambrx
Amgen
arGEN-X
Astellas Pharma
AstraZeneca
Bayer
Biogen Idec
BioNet Ventures
Biotest
BioWa
Boehringer Ingelheim
Bristol-Myers Squibb
Cancer Drugs Fund
CARBOGEN AMCIS
Cascadian Therapeutics, Inc.
Catalent Pharma Solutions
Celgene
Celldex Therapeutics
Cephalon
Cilag GmbH International
Clovis Oncology
Coldstream Laboratories
Concortis Biosystems
Corixa
Covagen
Crescendo Biologics
CSL Behring
CVie Therapeutics
CytomX Therapeutics
Daiichi Sankyo
Defiante Farmaceutica
Delenex Therapeutics
Domantis
Dutalys
Dyax
Eddingpharm
Eisai
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
ESBATech
Esperance Pharmaceuticals
ETH Zurich
FDA
Five Prime Therapeutics
Formation Biologics
Fresenius Biotech
F-Star
Fujifilm
Genentech
Genmab
Gilead Sciences
Glenmark
Glycart
Glycotope
Goodwin Biotechnology
GSK
Health Canada
Igenica
Immune Design
Immunocore
ImmunoGen
Immunomedics
IONTAS
Janssen Biotech
Jazz Pharmaceuticals
Kalobios
Karolinska Institute
Kyowa Hakko Kirin
Kyowa Medex
LINDIS Biotech
Lonza
MacroGenics
MedImmune
Merck
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus
Micromet
Millennium Pharmaceuticals
Molecular Partners
MorphoSys
MultiCell Immunotherapeutics (MCIT)
National Institute of Diabetes and Digestive and Kidney Diseases
Neopharm
Neovii Biotech
Nerviano Medical Sciences
NHS
NICE
NMS Group
Nordic Nanovector ASA
Novartis
Novartis Institutes for BioMedical Research (NIBR)
NovImmune
Oxford BioTherapeutics
Oxis Biotech
Pfizer
Pharmacyclics
Pieris
Piramal Enterprises
Piramal Healthcare
PolyTherics
ProBioGen
Progenics
ProStrakan
Redwood BioScience
Roche
Salix
Sanofi
Scil Proteins
Seattle Genetics
Servier
Shinogi
Shire
Sigma-Tau
Simcere Pharmaceutical Group
Sorrento Therapeutics
Spectrum Pharmaceuticals
Spirogen
Stelis Biopharma
Stemcentrx
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Synthon
Synthon Biopharmaceuticals
Takeda
Talon Therapeutics
Teva
TG Therapeutics
The American Society of Hematology
The University of Texas MD Anderson Cancer Center
TRION Pharma
UCB
WHO
Wyeth
Xencor
Zydus Cadila
Zymeworks

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.